These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32115542)

  • 21. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
    Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J;
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Risk Factors for Death Caused by Extended-Spectrum Beta-Lactamase: Producing Bacteria.
    Mita Y; Shigemura K; Osawa K; Kitagawa K; Kotaki T; Shirakawa T; Miyara T; Fujisawa M
    Urol Int; 2019; 102(2):205-211. PubMed ID: 30602152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward.
    Meini S; Laureano R; Tascini C; Arena F; Fani L; Frullini A; Passaleva MT; Roberts AT; Mannini D; Sbrana F; Ripoli A; Rossolini GM
    Eur J Intern Med; 2018 Feb; 48():50-56. PubMed ID: 29089174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity.
    To KK; Lo WU; Chan JF; Tse H; Cheng VC; Ho PL
    Int J Infect Dis; 2013 Feb; 17(2):e120-4. PubMed ID: 23098812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nosocomial extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia in hemodialysis patients and the implications for antibiotic therapy.
    Yang CC; Wu CH; Lee CT; Liu HT; Chen JB; Chiu CH; Chen CH; Chuang FR
    Int J Infect Dis; 2014 Nov; 28():3-7. PubMed ID: 25200093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.
    Lee NY; Lee CC; Li CW; Li MC; Chen PL; Chang CM; Ko WC
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7558-63. PubMed ID: 26416853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.
    Khoo AL; Zhao YJ; Teng M; Ying D; Jin J; Chee YL; Poon LM; Lim SE; Koh LP; Chng WJ; Lim BP; Hsu LY; Chai LYA
    Int J Antimicrob Agents; 2018 Sep; 52(3):350-357. PubMed ID: 29751120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
    Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
    Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia.
    Matsumura Y; Yamamoto M; Nagao M; Komori T; Fujita N; Hayashi A; Shimizu T; Watanabe H; Doi S; Tanaka M; Takakura S; Ichiyama S
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5107-13. PubMed ID: 26100708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
    Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
    J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea.
    Ahn JY; Ann HW; Jeon Y; Ahn MY; Oh DH; Kim YC; Kim EJ; Song JE; Jung IY; Kim MH; Jeong W; Ku NS; Jeong SJ; Choi JY; Yong D; Song YG; Kim JM
    BMC Infect Dis; 2017 May; 17(1):327. PubMed ID: 28468622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections.
    Xiao T; Wu Z; Shi Q; Zhang X; Zhou Y; Yu X; Xiao Y
    J Glob Antimicrob Resist; 2019 Jun; 17():147-156. PubMed ID: 30634054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis.
    Senard O; Lafaurie M; Lesprit P; Nguyen Y; Lescure X; Therby A; Fihman V; Oubaya N; Lepeule R
    Eur J Clin Microbiol Infect Dis; 2020 Jan; 39(1):121-129. PubMed ID: 31512147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis.
    Wu UI; Chen WC; Yang CS; Wang JL; Hu FC; Chang SC; Chen YC
    Int J Infect Dis; 2012 Jan; 16(1):e47-52. PubMed ID: 22055248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
    Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
    Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia.
    Ku NS; Kim YC; Kim MH; Song JE; Oh DH; Ahn JY; Kim SB; Kim HW; Jeong SJ; Han SH; Kim CO; Song YG; Kim JM; Choi JY
    Arch Gerontol Geriatr; 2014; 58(1):105-9. PubMed ID: 23988261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
    Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
    Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
    Sugimoto N; Yamagishi Y; Mikamo H
    J Infect Chemother; 2017 Jan; 23(1):65-67. PubMed ID: 27693013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.